Guidance on Biosimilar Licensure

Article

FDA published draft guidance for applicants seeking licensure of a proposed biosimilar or proposed interchangeable biosimilar.

On Feb. 6, 2020, FDA published draft guidance in a series of guidance documents developed to implement the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). The new draft guidance discusses licensure of biosimilars and interchangeable biosimilars for fewer than all conditions of use than the reference product. 

The guidance provides recommendations for applicants seeking licensure under section 351(k) of the Public Health Service (PHS) Act. It also provides recommendations on the submission of a supplement to a licensed 351(k) biologics license application (BLA) for those seeking to add a condition of use that previously has been licensed for the reference product to the labeling of a licensed biosimilar or interchangeable product. Additionally, the guidance discusses the development of proposed labeling and timing for the submission of a 351(k) BLA or supplement to a licensed 351(k) BLA.

Source: FDA

 

Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Related Content
© 2025 MJH Life Sciences

All rights reserved.